-
61.发明授权USE OF UROCORTIN OPTIONALLY TOGETHER WITH CORTICOTROPIN-RELEASING FACTOR AS THERAPEUTIC AGENTS 有权使用尿皮质醇和可选肾上腺皮质激素释放因子的治疗剂
公开(公告)号：EP2187940B1
公开(公告)日：2013-01-30
申请号：EP08802191.0
申请日：2008-09-09
发明人： BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
CPC分类号： A61K38/085 , A61K38/35 , Y02A50/385 , Y02A50/402 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/422 , Y02A50/423
摘要： The present invention is directed to the use of the peptide compound Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
-
公开(公告)号：EP2188016B1
公开(公告)日：2012-08-01
申请号：EP08802149.8
申请日：2008-09-09
发明人： BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
IPC分类号： A61K38/31 , A61P11/00 , A61P31/06 , A61P31/04 , A61P7/00 , A61P9/00 , A61P13/00 , A61P15/00 , A61P17/00 , A61P19/00
CPC分类号： A61K38/043 , A61K38/12 , A61K38/34 , Y02A50/385 , Y02A50/402 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/422 , Y02A50/423 , A61K2300/00
摘要： The present invention is directed to the use of the peptide compound H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
-
63.发明授权
公开(公告)号：EP2187954B1
公开(公告)日：2012-07-18
申请号：EP08802365.0
申请日：2008-09-09
发明人： BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
CPC分类号： A61K38/1729 , Y02A50/385 , Y02A50/387 , Y02A50/393 , Y02A50/397 , Y02A50/402 , Y02A50/406 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/423 , Y02A50/469
摘要： The present invention is directed to the use of the peptide compound Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
-
64.发明授权Ac-RFMWMR-NH2 for use in the treatment of Mycobacterium tuberculosis related diseases 有权AC-RFMWMR-NH2相关的用于结核分枝杆菌病的治疗
公开(公告)号：EP2187913B1
公开(公告)日：2012-07-11
申请号：EP08802152.2
申请日：2008-09-09
发明人： BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
CPC分类号： A61K38/085 , A61K38/35 , Y02A50/385 , Y02A50/402 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/422 , Y02A50/423
摘要： The present invention is directed to the use of the peptide compound Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
-
公开(公告)号：EP2227244A1
公开(公告)日：2010-09-15
申请号：EP08802438.5
申请日：2008-09-09
发明人： BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
CPC分类号： A61K38/22 , A23L33/18 , A23L33/40 , A23V2002/00 , Y02A50/385 , Y02A50/402 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/423 , A23V2200/308 , A23V2200/318 , A23V2200/322 , A23V2200/324 , A23V2200/326 , A23V2250/55
摘要： The present invention is directed to the use of the peptide compound Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-GIn-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
-
公开(公告)号：EP2205269A1
公开(公告)日：2010-07-14
申请号：EP08802440.1
申请日：2008-09-09
发明人： BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
IPC分类号： A61K38/23 , A61K38/22 , A61P3/00 , A61P9/00 , A61P11/00 , A61P25/28 , A61P31/00 , A61P35/00 , A61P37/00 , A61P31/14 , A61P37/06 , A61P31/04 , A61P1/04 , A61P31/12 , A61P11/06
CPC分类号： A61K38/12 , A61K38/09 , C07K14/58 , Y02A50/385 , Y02A50/402 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/423
摘要： The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
-
67.发明公开USE OF RFRP, ALONE OR IN COMBINATION WITH NEUROKININ-B, AS A THERAPEUTIC AGENT 审中-公开USE RFRP，单独地或与神经激肽-B的组合，作为治疗剂
公开(公告)号：EP2205267A1
公开(公告)日：2010-07-14
申请号：EP08835232.3
申请日：2008-09-09
发明人： BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
IPC分类号： A61K38/17 , A61K38/04 , A61P3/00 , A61P9/00 , A61P11/00 , A61P25/28 , A61P31/00 , A61P35/00 , A61P37/00 , A61P31/20
CPC分类号： A61K38/10 , Y02A50/385 , Y02A50/402 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/422 , Y02A50/423
摘要： The present invention is directed to the use of the peptide compound Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
-
68.发明公开USE OF THE PEPTIDE THYMOSIN BETA 4 ALONE OR IN COMBINATION WITH CECROPIN A AS A THERAPEUTIC AGENT 审中-公开肽胸腺素β4的联合使用阿天蚕素FOR 1型糖尿病或类风湿性关节炎的治疗
公开(公告)号：EP2205265A1
公开(公告)日：2010-07-14
申请号：EP08802436.9
申请日：2008-09-09
发明人： BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
IPC分类号： A61K38/17 , A61K38/22 , A61P3/00 , A61P9/00 , A61P11/00 , A61P25/28 , A61P31/00 , A61P35/00 , A61P37/00
CPC分类号： A61K38/08 , A61K38/1825 , Y02A50/385 , Y02A50/402 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/422 , Y02A50/423
摘要： The present invention is directed to the use of the peptide compound Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
-
69.发明公开USE OF LVV-HEMORPHIN-6 AND OPTIONALLY AF12198 AS THERAPEUTIC AGENT(S) 有权LVV haemorphin-6和可选AF12198作为治疗性（S）介质中使用
公开(公告)号：EP2197477A2
公开(公告)日：2010-06-23
申请号：EP08802215.7
申请日：2008-09-09
发明人： BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
IPC分类号： A61K38/20 , A61K38/08 , A61P3/00 , A61P9/00 , A61P11/00 , A61P25/28 , A61P31/00 , A61P35/00 , A61P37/00 , A61P31/06
CPC分类号： A61K38/35 , A61K38/10 , Y02A50/385 , Y02A50/402 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/423
摘要： The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pyr-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
-
70.发明公开
公开(公告)号：EP2197464A2
公开(公告)日：2010-06-23
申请号：EP08802073.0
申请日：2008-09-09
发明人： BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
CPC分类号： A61K38/08 , A61K38/11 , Y02A50/385 , Y02A50/402 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/422 , Y02A50/423 , Y02A50/471 , A61K2300/00
摘要： The present invention is directed to the use of the peptide compound Gly-Arg-Gly-Asp-Asn-Pro as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Gly-Arg-Gly-Asp-Asn-Pro optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
-
-
-
-
-
-
-
-
-
搜索结果
114 条记录 (耗时 0.051 秒)
